The Menarini Group, an Italy-based international pharmaceutical and diagnostics company, and United States-based Radius Health, Inc. (NASDAQ: RDUS) announced on Wednesday that the companies have submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for elacestrant in patients with ER+/HER2- advanced or metastatic breast cancer.
Under the submission, the companies have asked for Priority Review with the FDA. If Priority Review is granted, the firms expect that the FDA is to carry out an eight-month review, incorporating a six-month priority designation review. The NDA submission is based on positive phase three data from the EMERALD study.
The product is claimed to be the first and presently the only investigational oral SERD to indicate positive topline results in a pivotal trial for the treatment of ER+/HER2- advanced or metastatic breast cancer in postmenopausal women, and men. These outcomes indicated that the product is also active in patients whose tumours harbour an ESR1 mutation.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval